冠心病术后尼可地尔联合依洛尤单抗对心绞痛的疗效

Objective To explore the curative effect of nicorandil combined with evolocumab on angina pectoris after coronary heart disease operation. Methods A total of 97 patients with post-PCI angina due to coronary heart disease treated in our hospital were selected, with an inclusion period from February 2025 to October 2025. They were randomly divided into a control group and an observation group using a random number table, with 48 and 49 cases, respectively. The control group was given evolocumab injection, while the observation group received nicorandil in addition to the aforementioned drug treatment. The efficacy, serum lipid peroxidation levels [soluble CD40 ligand(sCD40L), soluble intercellular adhesion molecule-1(sICAM-1)], inflammatory factors [monocyte chemoattractant protein-1(serum MCP-1), interleukin-6(IL-6), interleukin-10(IL-10)], and adverse reactions of the two groups were compared. Results After treatment, the total effective rate of the observation group(93.88%) was higher than that of the control group(79.17%)(P<0.05). The observation group exhibited lower levels of sCD40L [(2.64±0.32) ng/mL], sICAM-1 [(82.83±10.17) ng/mL], serum MCP-1 [(226.42±13.11) ng/L], IL-6 [(6.43±1.23) ng/L], and IL-10 [(8.96±1.52) ng/L] compared with the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group(14.29%) and the control group(8.33%)(P>0.05). Conclusion For patients with angina pectoris after PCI for coronary heart disease, the use of nicorandil and evolocumab injection for treatment can improve the therapeutic effect and promote the recovery of patients.